Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.53 |
| ▸ | PTGES | O14684 | 3/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | DLAT | P10515 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | POLL | Q9UGP5 | 3/20 | 0.45 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 2/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14524549 | 1.00 | SIRT1 (0.53) | SIRT1SIRT2PTGESSLC6A2SLC6A4 | |
| SCHEMBL14524550 | 1.00 | SIRT1 (0.53) | SIRT1SIRT2PTGESSLC6A2SLC6A4 | |
| SCHEMBL31345797 | 0.93 | SIRT1 (0.60) | SIRT1SIRT2PTGESSLC6A2SLC6A4 | |
| SCHEMBL14524547 | 0.93 | SIRT1 (0.60) | SIRT1SIRT2PTGESSLC6A2SLC6A4 | |
| SCHEMBL31345913 | 0.93 | SIRT1 (0.60) | SIRT1SIRT2PTGESSLC6A2SLC6A4 | |
| SCHEMBL14524546 | 0.93 | SIRT1 (0.60) | SIRT1SIRT2PTGESSLC6A2SLC6A4 | |
| SCHEMBL14524552 | 0.93 | SIRT1 (0.60) | SIRT1SIRT2PTGESSLC6A2SLC6A4 | |
| SCHEMBL14524558 | 0.88 | SIRT1 (0.51) | SIRT1SIRT2PTGESSLC6A2SLC6A4 | |
| SCHEMBL14524556 | 0.84 | SIRT1 (0.52) | SIRT1SIRT2PTGESSLC6A2SLC6A4 | |
| SCHEMBL14141107 | 0.83 | PTGES (0.40) | SIRT1SIRT2PTGESSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100415219-C | Substituted bicyclo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients | SIEGFRIED SEEBER (US) | 2008-09-03 | — | — | CN | disclosed |
| US-7199161-B2 | Substituted bicylo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients | DIAGENICS INTERNATIONAL CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199161-B2 | Substituted bicylo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients | DIAGENICS INTERNATIONAL CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199161-B2 | Substituted bicylo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients | DIAGENICS INTERNATIONAL CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1448179-B1 | SUBSTITUTED BICYCLO 3.3.1 NONAN-2,4,9-TRIONES AS PHARMACEUTICAL ACTIVE INGREDIENTS | DIAGENICS INTERNAT CORP (US) | 2006-08-09 | — | — | EP | disclosed |
| CN-1615127-A | Substituted bicyclo [3.3.1] nonane-2, 4, 9-triones as active pharmaceutical ingredients | SIEGFRIED SEEBER (DE) | 2005-05-11 | — | — | CN | disclosed |
| US-20050090693-A1 | Substituted bicylo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients | DIAGENICS INTERNATIONAL CORPORATION | 2005-04-28 | — | — | US | disclosed |
| EP-1448179-A1 | SUBSTITUTED BICYCLO 3.3.1 NONAN-2,4,9-TRIONES AS PHARMACEUTICAL ACTIVE INGREDIENTS | Seeber, Siegfried (DE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003043622-A1 | SUBSTITUTED BICYCLO[3.3.1]NONAN-2,4,9-TRIONES AS PHARMACEUTICAL ACTIVE INGREDIENTS | SEEBER SIEGFRIED (DE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090693-A1 | Substituted bicylo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients | TK1, TK2, TERT | SIRT1 605/4885SIRT2 809/4885PTGES 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.